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Abstract
Cardiac fibrosis describes the inappropriate proliferation of cardiac fibroblasts (CFs), leading to accumulation of
extracellular matrix (ECM) proteins in the cardiac muscle, which is found in many pathophysiological heart
conditions. A range of molecular components and cellular pathways, have been implicated in its pathogenesis. In
this review, we focus on the TGF-β and WNT signaling pathways, and their mutual interaction, which have
emerged as important factors involved in cardiac pathophysiology. The molecular and cellular processes involved in
the initiation and progression of cardiac fibrosis are summarized. We focus on TGF-β and WNT signaling in cardiac
fibrosis, ECM production, and myofibroblast transformation. Non-coding RNAs (ncRNAs) are one of the main players
in the regulation of multiple pathways and cellular processes. MicroRNAs, long non-coding RNAs, and circular long
non-coding RNAs can all interact with the TGF-β/WNT signaling axis to affect cardiac fibrosis. A better
understanding of these processes may lead to new approaches for diagnosis and treatment of many cardiac
conditions.
Keywords: Cardiac fibrosis, TGF-β/WNT signaling, Non-coding RNAs
Introduction
Cardiac fibrosis and abnormal tissue remodeling are
pathological findings in many cardiac disorders, such as
myocardial infarction, hypertension, myocarditis, cardiac
hypertrophy, and dilated cardiomyopathy. These condi-
tions are associated with considerable morbidity and
mortality [1–3]. The process of cardiac fibrosis is
characterized by a disproportionate accumulation of
extracellular matrix (ECM) components. The transform-
ation of cardiac fibroblasts (CFs) to myofibroblasts is the
key step in this process, and plays a critical role in the
development of fibrosis [4]. When cardiomyocytes die
over a period of several days following a sudden cardiac
injury, activated myofibroblasts trigger the formation of
a fibrotic scar in the affected cardiac muscle [5]. Experi-
mental and clinical evidence has suggested that the
transformation of CFs could be regulated by the trans-
forming growth factor beta (TGF-β) and WNT (wingless
int1) signaling pathways. Experimental models have
shown increased expression of TGF-β and WNT pro-
teins, as key pro-fibrotic factors in cardiac fibrosis [6–8].
Noncoding RNAs (ncRNAs) can be classified into sev-
eral different types, including small microRNAs
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(miRNAs or miRs; ~ 22 nucleotides), long noncoding
RNAs (lncRNAs; > 200 nucleotides) and circular long
noncoding RNAs (circRNAs; > 200 circular nucleotides)
[9, 10]. All these ncRNAs have been implicated in the
regulation of specific cellular signaling pathways, such as
TGF-β and WNT, that act to regulate cytokine secretion
and extracellular matrix synthesis [11–13]. A growing
body of evidence points to cross-regulation between
these two pro-fibrotic pathways mediated via ncRNAs,
and its involvement in the pathophysiology of cardiac fi-
brosis. Understanding these mechanisms will be import-
ant to develop new therapeutic agents for treatment of
cardiac fibrosis [14–17]. In this review, we will first pro-
vide an overview of TGF-β and WNT signaling, and
their regulation, followed by a description of their role
in the pathogenesis of cardiac fibrosis. Next, we
summarize some recent experimental evidence for the
involvement of TGF-β and WNT signaling in vascular
and cardiac remodeling during fibrosis. Finally, the role
of ncRNAs, including miRNAs, lncRNAs, and circRNAs,
in TGF-β and WNT signaling in the heart. This is a rela-
tively new field that may provide new avenues for the
prevention and treatment of cardiac fibrosis.
TGF-β signaling
A growing body of evidence indicates that members of
the TGF-β family can play a major role in a wide range
of processes related to cardiac pathophysiology, includ-
ing cardiac repair, hypertrophy, fibrotic remodeling,
fibroblast activation, and extracellular matrix deposition
[18–23]. The TGF-β family is comprised of 33 members,
which are multifunctional cytokines interacting with
TGF-β receptors to trigger signaling cascade responses
in cells [24]. In mammals, the TGF-β isoforms (TGF-β1,
β2, and β3) are encoded by three different genes, that
are located on separate chromosomes [25–27]. Although
in vitro studies have suggested that the three isoforms
have similar properties, knockout experiments in mice
have shown that each TGF-β isoform exerts distinct ef-
fects in tissue development and differentiation in verte-
brates [28–31]. TGF-β is initially secreted as a latent
complex consisting of three proteins, including TGF-β,
latency-associated protein (LAP) and latent TGF-β–
binding proteins (LTBPs) so that it is inactive in its la-
tent form. This complex is proteolytically cleaved and
activated by an integrin-mediated process [32–34]. Upon
binding to their receptor, TGF-βs can activate various
processes which can be Smad-dependent (canonical re-
sponse) or Smad-independent (noncanonical response).
The Smad-dependent TGF-β signaling pathway is much
better documented. Once activated the TGF-β can bind
to heterodimeric receptors (consisting of TGF-β type I
and TGF-β type II receptors) and initiate a signaling cas-
cade mediated by the Smad family of transcription
factors [35–37]. In the presence of the TGF-β ligand,
TGF-β receptor I kinase promotes phosphorylation of
the receptor-activated Smads (R-Smads, Smad2 and 3),
which mediates the translocation of p-Smad into the nu-
cleus via binding to the common mediator, Smad4 [37].
In the nucleus, the R-Smad/Smad4 complex associates
with the transcriptional cofactor p300 and with Fast-1, a
nuclear DNA binding protein belonging to the Fast fam-
ily. This complex binds to DNA, leading to increased ex-
pression of the downstream effectors of the TGF-β
signaling pathway [38, 39]. There are fundamental differ-
ences between the processes mediated by Smad2 and
Smad3. Smad2 is required for normal development pro-
cesses, whereas Smad3 is required for TGF-β-induced
gene expression. Microarray analysis in adult Smad3−/−
and Smad3+/+ mice revealed that TGF-β did not induce
any transcription in Smad3−/− fibroblasts [40]. Intri-
guingly, in a recent report, Smad2 homozygous mice
(Smad2−/−) were not viable during embryogenesis, sug-
gesting that Smad2 is required for normal development
[41]. Two inhibitory Smads (I-Smad), named Smad6 and
Smad7, do not allow R-Smad phosphorylation, and pre-
vent subsequent nuclear translocation of R-Smad/Smad4
heterocomplexes, because they compete for the normal
binding of Smad2 and Smad3 to the TGF-β R1 [42].
After completion of the Smad transcriptional activity,
coactivator p300 facilitates an interaction between
Smad3 and the E3 ligase complex causing Smad3 ubiqui-
tination, leading to its degradation by the ubiquitin-
proteasome pathway [43, 44].
In addition, TGF-β can also result in direct activation
of a non-canonical response via three different pathways,
namely the PI3K/Akt, RhoA-ROCK axis and MAPK cas-
cades. In the PI3K/Akt pathway, activated TGF-β type I
receptor stimulates a signaling cascade involving
phosphatidylinositol-3-kinase (PI3K) and protein kinase
B (also known as Akt). In this pathway, PI3K activation
mediates phosphorylation and activation of Akt kinase,
which in turn modulates several downstream effectors,
such as the mammalian target of rapamycin (mTOR),
glycogen synthase kinase-3β (GSK-3β) and many others
[45, 46]. The second pathway involves Rho-associated
protein kinases (ROCKs) which are coiled-coil-
containing protein kinases existing in two isoforms,
ROCK1, and ROCK2 [47]. Experiments have confirmed
the importance of ROCKs in regulation of various cellu-
lar functions, especially cardiac fibrogenesis [48, 49]. It
has been demonstrated that inhibition of ROCK pre-
vented cardiac fibrosis in response to transverse aorta
constriction (TAC) and myocardial infarction (MI) [50].
In the third pathway, mitogen- activated protein kinases
(MAPKs) transmit the signal from the cell membrane to
the nucleus, and regulate gene expression through extra-
cellular signal-regulated kinase 1 and 2 (Erk1/2 or p44/
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42), c-Jun N-terminal kinases (JNKs), and the p38 iso-
forms (α, β, γ, and δ) [51]. The Smad-independent acti-
vation of MAPKs was confirmed by a study that found
that activation of MAPKs occurred in TGF-β treated
cells, even in the presence of Smad4-deficient or
dominant-negative Smads [52].
WNT signaling
Several publications have indicated the importance of
the WNT signaling cascade in normal development and
the pathogenesis of many diseases [53–56]. WNT li-
gands are highly conserved secreted glycoproteins, which
are transcribed from 19 genes in mammals, and are sub-
divided into 12 conserved subfamilies [57]. A family of
seven transmembrane receptors called Frizzled (Fz) act
as receptors for WNT ligands [58]. WNT ligands engage
the Fz receptors and the low-density-lipoprotein-recep-
tor-related proteins (LRP)5 and LRP6 act as co-receptors
resulting in the formation of a complex at the plasma
membrane. Activated Fz receptors activate not only the
β-catenin-dependent pathway, but also trigger a number
of β-catenin-independent signaling cascades.
In the WNT/β-catenin signaling pathway, the activated
Fz/LRP complex activates the Dishevelled (DVL) protein,
which interacts with a “destruction complex” comprised
of axin, adenomatous polyposis coli (APC), glycogen
synthase kinase 3 (GSK3), casein kinase 1 (CK1), plus
the ubiquitin ligase, β-TrCP. This destruction complex
normally causes the ubiquitination and consequent
destruction of β-catenin [59–61]. When the destruc-
tion complex binds to DVL it is inhibited, and β-
catenin escapes from ubiquitination and degradation
[62, 63]. Eventually, the stabilized β-catenin translo-
cates to the nucleus where it activates WNT-
responsive genes, by binding to T-cell factor/lymphoid
enhancer-binding factor-1 (TCF/Lef-1) transcription
factors, and other co-factors, such as p300 and CREB
binding protein (CBP) [56].
In the β-catenin-independent signaling pathway,
WNT4, WNT5a or WNT11 ligands can stimulate the Fz
receptor to trigger gene transcription, by activating the
planar cell polarity pathway, and a calcium-dependent
pathway. Signal transduction through the WNT/calcium
cell polarity pathway typically consists of protein kinase
C (PKC), calmodulin kinase II and calcineurin. Calcine-
urin is a Ca2 + −sensitive enzyme activated by Ca2+
release which results in elevated nuclear levels of the
AP-1/c-Jun transcription factor [64, 65]. In the planar
cell polarity pathway, certain MAPKs (JNK and ERK1/2
kinases) and the RhoA-ROCK axis act as important reg-
ulators to trigger signaling. In this pathway, WNT pro-
teins activate Rho signaling and Jun N-terminal kinase
(JNK) through DVL, leading to the modulation of cellu-
lar activity and polarity via ATF/CREB activation [66].
Endogenous WNT antagonists, such as the Dikkopf
(DKK) and secreted frizzled-related protein (sFRP)
families can regulate WNT signaling [67–69]. Many
studies have emphasized the key role of the WNT
signaling pathway in cardiac fibrosis, and it has been
suggested that regulation of signaling pathways might
be a useful pharmacological target for treatment of
cardiac disease [70–72].
Crosstalk between the TGF-β and WNT signaling
pathways
Recent studies have highlighted the extensive cross-talk
between the TGF-β and WNT pathways, which could be
responsible for the transcription of pro-fibrotic genes.
These pathways could create a positive feedback loop or
a negative feedback loop that impacts on the transcrip-
tional activity of other signaling cascades. For instance,
loss of the WNT co-receptor LRP5, in bleomycin-
induced lung fibrosis decreased the expression of TGF-
β1, and attenuated the induction of fibrosis [73]. Con-
sistently, over-expression of a constitutively active TGF-
β receptor type I in a mouse model (Ad-TBRIact-induced
fibrosis) enhanced the stability and nuclear accumulation
of β-catenin in primary cultured fibroblasts. These re-
sults showed that TGF-β activated the canonical WNT
pathway through a decrease in Dkk-1 via MAPKp38,
and this could be a major molecular mechanism for the
activation of the canonical WNT pathway [6]. In
addition, it was reported that sirtuin 3 (SIRT3) can in-
crease the enzymatic activity of GSK3, resulting in the
blockage of TGF-β expression in tissue fibrosis. The
SIRT3 deficiency induced GSK3β hyperacetylation
resulting in reduced GSK3β activity and lower
phosphorylation of Smad3, and β-catenin activation.
These events lead to stabilization and activation of
Smad3 and β-catenin transcription factors involved in
the tissue fibrosis process [74]. In addition, upon TGF-β
stimulation, the Axin, WNT scaffold protein, can pro-
mote Smad7 degradation by forming a complex with
Smad7 and the E3 ubiquitin ligase Arkadia [75]. Another
report revealed that Axin facilitated Smad3 binding to
the type I receptor to promote the tail-phosphorylation
of Smad3, which induced the transcription of pro-
fibrotic genes [76].
Furthermore, the microRNA, miR-29 inhibited the
synthesis of ECM caused by TGFβ1, through inhibition
of WNT3a/β-catenin signaling pathway in human orbital
fibroblasts [77]. Yeast two-hybrid and GST-pull down
assays showed a physical interaction between DVL-1 and
Smad3. Stimulation of the TGFβ pathway leads to an in-
crease in DVL-1, and Smad3 binding in vivo [78]. Co-
treatment with both WNT-3a conditioned medium, and
TGFβ led to enhancement of nuclear β-catenin, whereas
TGFβ alone had no effect. Moreover, Smad3 over-
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expression enhanced the ability of WNT-3a to increase
transcription, suggesting that Smad3 is required for the
effects of TGF-β on gene transcription [79]. The ability
of TGF-β to activate the canonical WNT signaling path-
way, and the functional impact of this mechanism on fi-
brotic processes has been reported in many organs, as
well as the heart [6, 80–82]. In summary, these data
point to the important role of TGF-β signaling in the ac-
tivation of the β-catenin-dependent pathway, and con-
versely, the role of the WNT/β-catenin signaling
pathway to trigger TGF-β signaling. Taken together, it
appears that mutual co-activation of these two pathways
is required to trigger the actual fibrotic response.
Cardiac fibrosis
Cardiac fibrosis is characterized by the increased activity
of cardiac fibroblasts, resulting in the accumulation of
ECM proteins (e.g. collagen I and III), which produce in-
creased myocardial stiffness, and thereby increase the
risk of heart failure and sudden cardiac death [83]. Car-
diac fibrosis commonly occurs in several types of cardio-
vascular disease, such as those caused by diabetes,
ischemia, aging, and inherited cardiomyopathy, which
cause considerable morbidity and mortality [1–3].
Healthy heart tissue consists of endothelial cells, vascular
smooth muscle cells, fibroblasts, and myocytes [84–86].
The alteration of the collagen matrix results from
dysregulation of the balance between pro-fibrotic and
anti-fibrotic factors, including cytokines, chemokines,
hormones, growth factors, and proteases. This dysregu-
lation causes a swing in the balance, leading to excess
synthesis or inhibition of degradation [87]. Fibroblasts
are involved in collagen formation and degradation, and
any derangement in this process leads to collagen expan-
sion and myocardial fibrosis [88]. The key event in car-
diac fibrosis is the transformation of cardiac fibroblasts
(CFs) into myofibroblasts, which are involved in ECM
production, and accelerating the fibrotic process follow-
ing cardiac injury. After cardiac ischemia, cardiomyo-
cytes gradually die over a period of several days starting
after myocardial infarction, and then myofibroblasts re-
place the dead cells, and largely produce the fibrotic scar
[5]. There are two main stages in myofibroblast trans-
formation: in the first stage, small adhesion complexes
and stress-fiber network formation occurs to develop
proto-myofibroblasts from fibroblasts, and to facilitate
the migration of these cells into the injured tissue. In the
second stage, these proto-myofibroblasts convert to ma-
ture myofibroblasts which secrete alpha-smooth muscle
actin (α-SMA) and cadherin-11 by approximately 20–30
h following cardiac injury [89–91]. Activated myofibro-
blasts deposit large amounts of ECM proteins in the in-
farcted area [92]. In cardiovascular disease, myocardial
fibrosis can be divided into three stages: mild diffuse fi-
brosis, severe diffuse fibrosis, and segmental fibrosis.
Finding an effective treatment for myocardial fibrosis
is a major clinical challenge, which may dramatically
improve the survival rate and the quality of life in pa-
tients. Cardiac magnetic resonance (CMR) imaging has
been used to evaluate the extent of diffuse myocardial fi-
brosis, and for monitoring patients with cardiac fibrosis
[93–95]. In one study by McCrohon and colleagues,
myocardial fibrosis was assessed in patients suffering
from dilated cardiomyopathy (DCM) using gadolinium-
CMR demonstrating high sensitivity, specificity, and
good spatial resolution. The results suggested that ap-
proximately one third of patients with DCM may have
myocardial scarring or fibrosis [96]. Therefore, CMR im-
aging techniques may be used to delineate foci of fibrosis
in patients with DCM. Myocardial fibrosis is associated
with electrical dysfunction that leads to ventricular ar-
rhythmias in tricuspid atresia patients [97]. Ventricular
myofiber disorganization and interstitial fibrosis have
been demonstrated in patients with tetralogy of Fallot
[98]. A study revealed increased macroscopic fibrosis in
the left ventricles (LV) of deceased patients with con-
genital aortic stenosis and coarctation [99]. Also, LV fi-
brosis has been detected in patients with idiopathic
DCM who only had mild symptoms. The data suggested
that collagen accumulation might be responsible for the
impaired LV diastolic function found in these patients
[100]. Various alterations in molecular pathways and cel-
lular effectors have been shown to occur in various car-
diac fibrotic conditions, and it is important to assign the
relative contribution(s) of each pathway, and the thera-
peutic implications. Therefore, the effectiveness of anti-
fibrotic strategies requires a better understanding of the
mechanisms of cardiac fibrosis, which may depend on
the underlying etiology, severity and extent of disease.
The role of TGFβ and WNT signaling in cardiac fibrosis
Myofibroblasts expressing expressed α-SMA (smooth
muscle actin) are mainly involved in the excessive syn-
thesis and degradation of collagen in cardiac fibrosis [4,
101]. Following a cardiac injury, fibroblasts transdiffer-
entiate into myofibroblasts, which are normally absent in
the healthy heart. Myofibroblasts are in between a fibro-
blast and a smooth muscle cell in phenotype [102, 103].
Myofibroblasts mainly secrete ECM proteins, such as
periostin, collagens I and III, and fibronectin, and also a
number of cytokines which regulate the inflammatory
response at the injury site [89]. In heart disease, fibrotic
remodeling associated with cellular and molecular mech-
anisms, leads to disturbance of cardiac function in differ-
ent ways. Myocardial fibroblasts are stimulated both
mechanically and chemically to undergo differentiation
into the myofibroblast phenotype [104]. The TGF-β and
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WNT signaling pathways are two key regulators of myo-
fibroblast biology in cardiac fibrosis [56, 105–107]. High
expression levels of TGF-β1 (a prototypical fibrogenic
cytokine) has been reported during cardiac fibrosis both
in humans and experimental models [108, 109]. The in-
crease in TGF-β causes nuclear accumulation of Smad2/
3 in myofibroblasts, and decreases the inhibitory Smad6
and Smad7, thereby inducing the activation of numerous
pro-fibrotic genes [21, 110, 111]. The resistance of fibro-
blasts isolated from Smad3 −/− mouse embryos to TGF-
β1 induction of ECM proteins, confirmed that Smad3
mediated TGF-β transactivation of these ECM pro-
moters [40, 112]. In the injured heart, the Smad3 signal-
ing cascade may be the first step in myofibroblast
differentiation by promoting α-SMA transcription [113].
In α-SMA-positive myofibroblasts, TGFβ1 could up-
regulate matrix proteins (such as ED-A fibronectin) and
increase the deposition of collagen sub-types (such as
collagens I, III, and VI) by regulating the levels of plas-
minogen activator inhibitor (PAI)-1 and tissue inhibitor
of metalloproteinases (TIMPs), and also by regulating
the levels of other pro-fibrotic cytokines [114–116]. Col-
lagen type VI plays a role in cardiac remodeling by in-
creasing myofibroblast differentiation, whereas collagen
types I and III stimulate the proliferation of CF via in-
creasing ERK1/2 activity [117]. WNT/β-catenin signaling
is enhanced in areas of scar formation, and in epicardial
activation in mouse models [118]. Activation of the
WNT/β-catenin pathway by TGF-β is well-documented.
TGF-β increases Akt phosphorylation through PI3K acti-
vation, thus inactivating GSK3β (an enzyme involved in
β-catenin degradation), which promotes cardiac fibrosis
[119]. In recent years, a number of reports have indi-
cated that the canonical WNT/β-catenin pathway, and
Smad-dependent TGF-β signaling are involved in the
stimulation of myofibroblast proliferation and differenti-
ation, thus promoting fibrogenesis [120, 121]. WNT3a
can promote migration in cultured fibroblasts, as well as
the adoption of a myofibroblast-like phenotype, in part
by up-regulation of TGF-β signaling through Smad2.
WNT3a-induced α-SMA expression was reversed fol-
lowing knockdown of β-catenin, suggesting that fibrosis
was dependent on canonical WNT signaling through β-
catenin [14]. GSK-3β exerts a novel and central role in
regulating myocardial fibrotic remodeling via modula-
tion of canonical TGF-β1 signaling through direct
interaction with Smad-3. Moreover, genetic and pharma-
cological approaches have demonstrated that inhibition
of GSK-3β can induce the transformation of fibroblasts
to myofibroblasts [122]. In cardiac fibroblasts, over-
expression of FGF23 promoted fibroblast proliferation
through activation of β-catenin signaling, leading to
TGF-β up-regulation [15]. In primary cardiac fibroblasts,
lack of endogenous sFRP-1 increased αSMA and
collagen expression, and promoted differentiation of fi-
broblasts into myofibroblasts [71]. Over-expression of
sFRP2 significantly reduced ventricular fibrosis, and im-
proved cardiac function in vivo [123]. On the other
hand, sFRP2 antibody therapy decreased apoptosis and
fibrosis, and improved cardiac function in a hamster
model of heart failure [124]. In agreement with this,
mice lacking the sFRP2 gene that were subjected to
myocardial infarction, exhibited a reduction in cardiac fi-
brosis [125]. These findings suggest that sFRPs have
multiple modes of action in fibrotic processes. In a
WNT1 Cre transgenic mouse model subjected to myo-
cardial ischemia, WNT 1 expression occurred within 2
days following ischemia, with high expression levels
found in both epicardial cells and cardiac fibroblasts. Ex-
perimental models using CF-specific loss of β-catenin, or
exogenous over-expression of WNT1, have suggested
that canonical WNT signaling can induce collagen gene
expression during cardiac fibrosis. Chromatin immuno-
precipitation (ChIP) assays with an anti-β-catenin
antibody, showed that the β-catenin/LEF/TCF transcrip-
tional complex directly bound to ECM genes in CFs
[126]. In agreement with these studies, Dickkopf-3
(DKK3), a WNT signaling pathway inhibitor, attenuated
cardiac fibrosis in cardiac hypertrophy induced by ad-
ministration of angiotensin II (AngII), by promoting
AngII degradation. DKK3 inhibited the phosphorylation
of the metalloproteinase enzyme known as “a disintegrin
and metalloproteinase 17” (ADAM17), which in turn in-
creased angiotensin converting enzyme 2 expression,
and subsequently increased AngII degradation. AngII
degradation was triggered by the inhibition of GSK-3β
and β-catenin, and the decreased translocation of β-
catenin to the nucleus. On the other hand, DKK3 knock-
down by siRNA achieved the opposite effects [127]. The
blocking of the TGFβ and WNT pathways prevented the
development of fibrosis in animal models, but whether
these two signaling pathways contribute to chronic
pathologic fibrosis in humans is still unknown. Figure 1
and Table 1 illustrate the WNT and TGFβ signaling
pathways which have been associated with the pathogen-
esis of cardiac fibrosis.
Non-coding RNAs
ncRNAs play important roles in many cellular processes.
Based on nucleotide length, they are classified into: small
miRNAs (22 nucleotides) and lncRNAs (> 200 nucleo-
tides) [138, 139]. Circular RNAs (circRNAs) are a new
type of ncRNAs that can regulate gene expression and
protein production by acting as an miRNA sponge
[140–142]. These three groups of ncRNAs can be de-
tected in blood and other body fluids, such as urine and
breast milk, and can act as powerful tools for detection
and therapy of cardiac diseases, including cardiac fibrosis
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[4, 50, 143]. The function of ncRNAs during cardiac re-
modeling, involves them being secreted from some cells,
and then being actively taken up by other target cells,
thus contributing to cell–cell communications and para-
crine signaling pathways [144–148].
The role of ncRNAs in cardiac fibrosis
The role of ncRNAs (especially miRNAs) has been
shown in many studies [149–152]. The down-regulation
of miR-122 has been reported in endomyocardial biop-
sies from patients with severe aortic valve stenosis (AS),
compared to control subjects. Experiments in human fi-
broblasts have shown that miR-122 might be involved in
myocardial fibrosis [153]. In one recent study, miR-34a
was suggested to be a positive regulator of fibrogenesis.
miR-34a was dynamically up-regulated following myo-
cardial infarction, and inhibition of miR-34a resulted in
decreased severity of cardiac fibrosis in mice. Function-
ally, miR-34a over-expression increased the pro-
fibrogenic activity. miR-22 is also involved in regulation
of cardiac fibrosis. miR-22 was significantly reduced fol-
lowing myocardial infarction, leading to increased colla-
gen deposition, thereby promoting cardiac fibrosis. Some
ECM proteins, including Col1a1 and Col3a1, were over-
expressed after miR-22 knock-down in cultured CFs.
Another study demonstrated that miR-29 levels were de-
creased under cardiac stress, thereby increasing collagen
expression and promoting cardiac fibrosis [154]. Over-
expression of several lncRNAs, including n379599,
n379519, n384648, n380433, and n410105, increased the
expression of Col8A1, Col3A1, and FBN1 and increased
cardiac fibrosis by inducing phosphorylation of Smad2/3
and TGF-β signaling. Silencing of these lncRNAs in-
duced the opposite effect [12]. The over-expression of
Fig. 1 Role of WNT/TGFβ signaling pathways in pathogenesis of cardiac fibrosis. Simplified scheme showing the WNT/β-catenin pathway, and
Smad-dependent TGF-β signaling are involved in the stimulation of myofibroblast proliferation and differentiation, thus promoting fibrogenesis
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miR-1954 showed a reduction in cardiac mass and blood
pressure in mice. It also reduced expression of cardiac fi-
brotic genes, inflammatory genes, and hypertrophy
marker genes. They found that miR-1954 played an im-
portant role in cardiac fibrosis by targeting THBS1,
therefore it could be a promising strategy for the treat-
ment of cardiac fibrosis [155].
CircRNAs are another type of single-stranded RNA
molecules, which are involved in many normal physio-
logical processes, as well as the pathogenesis of cardio-
vascular disease [156, 157]. For example, circHIPK3
affected the proliferation and migration of CFs, and the
expression of genes such as COL1A1, COL3A1, α-SMA
through “sponging up” miR-29b-3p. Silencing of cir-
cHIPK3 showed opposite effects on CF proliferation,
and the diastolic function was improved in vivo [158].
Microarray analysis of several circRNAs revealed a sig-
nificant up-regulation of circRNA_010567 in a diabetic
db/db mouse model compared to controls. Knockdown
of circRNA_010567 reduced the synthesis of fibrotic
proteins, such as Col I, Col III and α-SMA in CFs, which
had been treated with Ang II [13]. ncRNAs could be at-
tractive candidates as putative biomarkers for cardiac fi-
brosis in a variety of cardiovascular conditions, although
their function needs to be fully investigated in future
studies.
Role of ncRNAs in TGFβ and/or WNT signaling
The relationship between ncRNAs and TGFβ and/or
WNT signaling has been demonstrated in studies, and
could affect many pathogenic conditions. Colorectal can-
cer patients with high expression of certain lncRNAs
had a shorter overall survival and a worse response to
chemotherapy. It was found that these lncRNAs pro-
moted CRC progression by activating Wnt/ β -catenin
pathway through activator protein 2 α. Furthermore,
lncRNA can induce multidrug resistance through acti-
vating Wnt/ β-catenin signaling by up-regulating
MDR1/P-gp expression [159].
Wu et al. showed that down-regulation of lncRNA
CCAT2 reduced the expression of TGF-β, Smad2 and α-
SMA in breast cancer patients. CCAT2 promoted
growth and metastasis of breast cancer by regulating the
TGF-β signaling pathway [160].
Shan et al. found that over-expression of lncRNA
Linc00675 inhibited the proliferation and migration of
colorectal cancer cells. Furthermore, they found that the
expression of miR-942 in clinical colorectal cancer tis-
sues was higher than in normal tissue. More import-
antly, the inhibitory effect of Linc00675 was also
attenuated by a miR-942 mimetic, suggesting that down-
regulation of miR-942 represented one of the mecha-
nisms by which Linc00675 inhibited the proliferation
and metastasis of colorectal cancer. They demonstrated
the inhibition of Wnt/β-catenin signaling in the
Linc00675/miR-942 regulated pathway in colorectal can-
cer cells [161].
Yoan et al. found that over-expression of lncRNA
CTD903 inhibited invasion and migration of colorectal
cancer cells by repressing Wnt/β-catenin signaling and
predicts favorable prognosis [162]. LncTCF7 is a lncRNA
which required for liver cancer stem cell self-renewal
and tumor progression. lncTCF7 recruited the SWI/SNF
complex to the promoter of TCF7 to regulate its
Table 1 TGFβ and WNT signaling pathways involved in the regulation of cardiac fibrosis
Pathway Function model Anti-fibrotic or
pro-fibrotic)
Reference
Aldehyde dehydrogenase-2 (ALDH2) Decreased β-catenin, phosphorylated GSK-3β, and
WNT-1
MI/rat Anti [128]
WNT10b Increased Axin2, Lef1 and Tcf7 Transgenic (TG)
WNT10b mice
Anti [129]
S100A4 Decreased β-catenin and phosphorylated β-catenin LAD /mouse; CFs Pro [130]
WNT3a and WNT5a Decreased glycogen synthase kinase 3β (GSK3β) Human CFs Pro [131]
Qishen Granule (QSG) Inhibition of the TGF-β/Smad3 pathway and the
phosphorylation of GSK-3β
HF/Rat Anti [132]
Xinfuli Granule (XG) Decreased Smad3, P-Smad3 and Smad2 protein MI/rat Anti [133]
Human antigen R (HuR) Increased TGF-β1 TAC/HuR-deletion
mouse
Pro [134]
Transient receptor potential ankyrin 1
(TRPA1)
Decreased TGF-β, IL-4 and IL-10 TAC/mouse Pro [135]





Increased TGF-β/Smad3 pathway and STAT3 Ang II MI/ Mouse Pro [137]
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expression, leading to activation of Wnt signaling.
lncTCF7-mediated Wnt signaling primes liver cancer
stem cell self-renewal and tumor propagation [163].
In addition to lncRNAs, microRNAs have important
roles in TGFβ and/or WNT signaling. Yu et al. found
that microRNA-21 induces stemness by down-regulating
TGF-β receptor 2 (TGFβR2) in colon cancer cells [164].
Tan et al. studied human orbital fibroblasts to show that
TGFβ1 treatment decreased miR-29 expression, which
could inhibit TGFβ1. MiR-29 inhibited TGFβ1-induced
proliferation and decreased colony formation of orbital
fibroblast cells after TGFβ1 treatment. MiR-29 mediates
TGFβ1-induced extracellular matrix synthesis through
activation of Wnt/β-catenin pathway in human orbital
fibroblasts [77].
In another study, salvianolic acid B (Sal B) treatment
induced the inactivation of the Wnt/β-catenin pathway,
with an increase in phosphorylated-β-catenin and Wnt
inhibitory factor 1. It was found that miR-17-5p was re-
duced in vivo and in vitro after Sal B treatment. As con-
firmed by luciferase activity assays, WIF1 was a direct
target of miR-17-5p. Importantly, the suppression of
HSCs induced by Sal B was almost completely inhibited
by miR-17-5p mimetics. Therefore, miR-17-5p activates
Wnt/β-catenin pathway to result in HSC activation
through inhibiting WIF1 expression [165].
The relationship between ncRNAs and TGFβ and/
or WNT signaling in cardiac fibrosis
Many studies have provided evidence for cross-talk be-
tween fibrosis development and miRNA deregulation,
via the TGFβ and WNT signaling pathways (Fig. 2).
Some of these studies are summarized in this section
(Tables 2, 3 and 4).
For example, researchers found that TGF-β1 and miR-
21 expression were up-regulated in the border zone of
mouse heart after myocardial infarction, whereas TGF-β
receptor type III was down-regulated. TGFβRIII is a
negative regulator of the TGF-β pathway. Over-
expression of miR-21 attenuated TGFβRIII expression in
cardiac fibroblasts, thereby potentially contributing to
excessive ECM production via the TGF-β pathway [166].
However, using miR-21–knockout mice and knock-
down of miR-21 expression, showed that cardiac fibrosis
Fig. 2 The crosstalk between microRNAs and WNT/TGFβ signaling pathways in cardiac fibrosis. Schematic representation that shows microRNAs
affect cardiac fibrosis progression by targeting WNT/TGFβ signaling pathway associated proteins
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could still develop under conditions of cardiac stress.
These data suggested that miR-21 was not essential for
pathological cardiac remodeling [167]. In animal models
of myocardial infarction, miR-101 is usually repressed,
and delivery of miR-101 by an adeno-associated virus
led to amelioration of the infarcted heart through activa-
tion of the proto-oncogene c-fos and silencing of the
TGFβ1 pathway [168]. miR-133a was down-regulated in
a model of atrial fibrillation in dogs, induced by adminis-
tration of nicotine. Over-expression of miR-133a
decreased TGF-β1 and levels of TGF-β receptor type II,
and also reduced the collagen content in cultured atrial
fibroblasts [169]. AS mentioned above, miR-34a over-
expression increased the pro-fibrogenic activity, whereas
miR-34a inhibition reduced the activity of TGF-β1 by
directly targeting Smad4 in CF cells [11]. Furthermore, it
is suggested that direct down-regulation of TGFβ by
miR-22 may have mediated the anti-fibrotic effect. miR-
29 may also play a role in the regulation of cardiac fibro-
sis. In a mouse model of aortic aneurysm, inhibition of
Table 2 miRNAs involved in the regulation of cardiac fibrosis mediated by TGFβ/WNT signaling pathways
miRNAs Expression (up/
down)
Function model Anti- fibrotic Pro-
fibrotic
Reference
miR-378 Down Activate RTK, GRB-2/TGFβ AngII, TAC/mouse; CFs Anti [179]
miR-101a Down Suppress TGFβ receptor I,
p-Smad3
MI, hypoxia/rat Anti [180]
miR-145 Up Suppress TGFβ receptor II Smooth muscle cells;
Ang II/mouse
Anti [181]
miR-675 Down Suppress TGFβ receptor I TGFb /mouse CFs Anti [182]
miR-10a Up Activate TGF-β1/Smads signaling pathway Rat CFs Pro [183]
miR-15 Up Suppress TGFβ receptor I, p38, endoglin,
Smad3/7
TAC/mouse Anti [184]
miR-9 Down Suppress TGFβ receptor II High glucose/human CFs Anti [185]
miR-223 Up Suppress RASA1 /Activate RAS and smad
signaling pathways
MI/ Rat CFs Pro [186]
MiR-
323a-3p
Up Suppress TIMP3/ActivateTGF-β pathway AngII, TAC/mouse; CFs Pro [187]
miR-202-
3p
Down Suppress TRPM6, TGFβ1, Smad2 and p- Smad2 Rat myocardial ischemic-reperfusion
(I/R) injury
Anti [188]
miR-433 Up Activate TGFβ1, ERK, p38 kinase and Smad3 MI/mice Pro [189]
miR-29b Down Suppress Smad3 signaling MI/Rat Anti [190]
miR-495 Down Suppress NOD1, NF-κB and TGFβ1/Smad signal-
ing pathways
High glucose/human CFs Anti [191]
miR-154 Up Suppress GSK-3β/ Activate WNT signaling Human CFs Pro [192]
miR-154 Up Suppress DKK2/ Activate WNT signaling Human CFs Pro [193]
miR-199a Up Suppress secreted frizzled-related protein 5
(SFRP5)
ISO, Rat CFs Pro [194]
miR-503 Up Activate connective tissue growth factor (CTGF)
and TGF-β
AngII, TAC/mouse; CFs Pro [195]
Table 3 LncRNAs involved in the regulation of cardiac fibrosis mediated by TGFβ/WNT signaling pathways
LncRNAs Expression
(up/down)
Function Model Anti- fibrotic
or Pro-fibrotic
Reference





Taurine Upregulated Gene 1
(TUG1)
Up Sponged miR-29c/Activated TGFβ signaling
pathway
Congenital human heart









Down Inhibited the binding of Smad3 to the α-
SMA gene promoter via interacting with
rSBEs
DCM/Human, mouse/CFs Anti [199]
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miR-29 led to greater stability in the aortic walls, and
prevented rupture by increasing the expression of several
ECM genes, such as Col1A1, Col3A1, and elastin [170].
It is indicated that TGFβ could repress miR-29 expres-
sion under cardiac stress [154]. Suppression of miR-155
reduced infarct size, improved LV function, and attenu-
ated collagen deposition in vivo. Knockout of miR-155
arrested the proliferation of CFs and their differentiation
into myofibroblasts, through up-regulation of “tumor
protein p53-inducible nuclear protein1” (TP53INP1)
[171]. TP53INP1 is a pro-apoptotic protein that can
interact with p53 and modulate p53 transcriptional ac-
tivity [172]. A previous report showed that TGF-β could
indirectly regulate TP53INP1 expression by affecting
miR-155 levels in liver cancer cells [173]. miR-24 also
plays a role in the regulation of myocardial infarction-
induced cardiac fibrosis, possibly through targeting furin
[174]. Furin is a protease related to the TGF-β pathway,
and has been reported to regulate production of collagen
in fibrosis [175]. A different study revealed that up-
regulation of a LncRNA, also known as “myocardial in-
farction associated transcript” (MIAT), in myocardial in-
farction was accompanied by down-regulation of miR-24
and up-regulation of Furin and TGF-β1 [176]. One
lncRNA, known as HOTAIR (HOX transcript antisense
RNA) was associated with myocardial fibrosis via activa-
tion of the WNT signaling pathway through targeting
the URI1 gene (unconventional prefoldin RPB5 interac-
tor 1). HOTAIR over-expression elevated the expression
of axin2, β-catenin and p-GSK-3β, and also promoted
cell proliferation and migration in CFs. Results showed
that the regulatory effects of HOTAIR over-expression
on CF functions were the same as those found after
URI1 over-expression, suggesting that HOTAIR may
regulate CFs by targeting URI1 [12].
Seo et al. showed that miR-384-5p was a key mediator
in the formation of a transactivation circuit between the
TGF-β and WNT signaling pathways in cardiac fibrosis.
This function might be related to the modulation of dif-
ferent receptors, such as Fzd1, Fzd2, TGFβR1, and
LRP6. The expression of miR-384-5p was significantly
decreased in CFs at 3 and 7 days after ischemia/reperfu-
sion (I/R) injury, and 24 h after TGF-β treatment. More-
over, the over-expression of miR-384-5p significantly
attenuated cardiac fibrosis and decreased the fibrotic
area in the rat I/R injury model. These findings sug-
gested that miR-384-5p might be able to control cardiac
fibrosis [177]. A recent study reported that inhibition of
miR-27a exhibited a cardio-protective effect by regulat-
ing the WNT and TGF-β pathways, through modulating
the expression of the β-catenin, p-GSK-3β and α-SMA
genes. According to this investigation, miR-27a levels
were increased in the fibrotic heart tissue of rats with
chronic heart failure (CHF), and the data suggested that
miR-27a might be a target for treating cardiac fibrosis
[17]. Furthermore, circRNA_010567 regulated TGF-β
signaling and ECM synthesis via sponging up miR-141
[178]. Moreover, it has been reported that CircActa2
was involved in myocardial and endocardial fibrosis,
through regulation of the expression and function of α-
SMA, by acting as a decoy for miR-548f-5p. It was
shown that TGF-β over-expression increased cir-
cACTA2, thereby facilitating the formation of stress fi-
bers and cell contraction [13].
Conclusions
The relentless progression of fibrosis is well known to
be a pathological finding in many cardiac conditions.
The mechanisms responsible for this process are rather
complex, and involve multiple pathways. Therefore, a
better understanding of the functional characteristics
and molecular profiles of these fibrotic processes could
provide solutions for the prevention and treatment of fi-
brotic lesions in the heart. Accumulating evidence points
to the cross-talk between the TGF-β and WNT signaling
pathways in the pathogenesis of cardiac fibrosis. Al-
though the cell biology of the TGF-β and WNT path-
ways has been well-described in cellular development
and in the pathophysiology of many diseases, the mecha-
nisms of these pro-fibrotic pathways in cardiac patholo-
gies is less well-understood. As discussed in this review,
canonical WNT signaling and TGF-β signaling can com-
bine together to regulate fibrotic processes in the heart,
and is likely to play a key role in switching on the gen-
etic machinery for the pro-fibrotic changes. ncRNAs
have increasingly been recognized to play possible roles
in strategies for combating CVDs, as described above.
Recent studies in the ncRNA field that are described in
this review, also indicate the important function of
ncRNAs in the regulation of cell signaling pathways,
Table 4 Circular RNAs involved in the regulation of cardiac fibrosis mediated by TGFβ/WNT signaling pathways
CircRNAs Expression (up/
down)










CircACTA2 Up Regulated the expression and function of α-SMA, by acting as
a decoy for miR-548f-5p.
TGF-β over-expression increased circACTA2.
Rat, mouse, and human
VSMCs
Pro [13]
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especially TGFB and WNT signaling. Information gath-
ered from these experiments, and identification of the
signaling pathways of the ncRNAs involved with cardiac
fibrosis, may lead to a new target for treatment strategies
for cardiac fibrosis. Additional research is needed to
identify the exact details of the mechanism by which the
ncRNA network affects cardiac fibrosis through TGFβ/
WNT signaling. Moreover, the possible clinical import-
ance of these TGFβ/WNT related ncRNAs, such as the
use of microRNAs as therapeutic tools, and circRNAs as
diagnostic/prognostic biomarkers for cardiac fibrosis
should be examined in additional animal and clinical
trials.
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